NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 52 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $1,000 | 0.0% | 894 | 0.0% | 0.00% | – |
| Q4 2016 | $1,000 | 0.0% | 894 | 0.0% | 0.00% | – |
| Q3 2016 | $1,000 | – | 894 | 0.0% | 0.00% | – |
| Q2 2016 | $0 | -100.0% | 894 | -99.1% | 0.00% | – |
| Q1 2016 | $93,000 | -30.1% | 100,844 | +0.9% | 0.00% | – |
| Q4 2015 | $133,000 | -41.7% | 99,950 | 0.0% | 0.00% | – |
| Q3 2015 | $228,000 | +41.6% | 99,950 | 0.0% | 0.00% | – |
| Q2 2015 | $161,000 | -1.2% | 99,950 | -2.8% | 0.00% | – |
| Q1 2015 | $163,000 | -19.7% | 102,779 | -4.2% | 0.00% | – |
| Q4 2014 | $203,000 | +42.0% | 107,312 | -0.4% | 0.00% | – |
| Q3 2014 | $143,000 | -8.3% | 107,738 | +2.3% | 0.00% | – |
| Q2 2014 | $156,000 | -13.3% | 105,343 | +8.0% | 0.00% | – |
| Q1 2014 | $180,000 | -10.9% | 97,523 | 0.0% | 0.00% | – |
| Q4 2013 | $202,000 | -24.9% | 97,523 | -4.1% | 0.00% | – |
| Q3 2013 | $269,000 | -5.3% | 101,717 | -4.6% | 0.00% | -100.0% |
| Q2 2013 | $284,000 | – | 106,582 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Platinum Management (NY) LLC | 15,575,946 | $14,711,000 | 89.51% |
| Financial Advisory Group | 10,000 | $356,000 | 0.17% |
| COMMERZBANK AKTIENGESELLSCHAFT /FI | 6,704,067 | $6,332,000 | 0.05% |
| LifePlan Financial Group, Inc | 28,810 | $27,000 | 0.02% |
| Greenwich Wealth Management LLC | 65,066 | $61,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 649,880 | $614,000 | 0.01% |
| LYNCH & ASSOCIATES/IN | 18,000 | $17,000 | 0.01% |
| SII INVESTMENTS INC/WI | 90,315 | $86,000 | 0.01% |
| Stratos Wealth Partners, LTD. | 42,535 | $40,000 | 0.00% |
| SVB WEALTH LLC | 46,262 | $44,000 | 0.00% |